Investors with an interest in Medical - Dental Supplies stocks have likely encountered both The Cooper Companies (COO) and West Pharmaceutical Services (WST) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a prove ...

Investors interested in Medical - Dental Supplies stocks are likely familiar with Becton Dickinson (BDX) and Straumann Holding AG (SAUHY) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate re ...

The Zacks Medical - Dental Supplies industry in the Medical sector is likely to continue its upward momentum in 2026, backed by persistent innovation, an aging population with increasing healthcare needs and normalized orders following significant destocking since COVID-19.In 2026, the industry is likely to see continued adoption of digital services and AI-enabled assessment tools that enhance patient experience and reduce administrative burdens for physicians. These services support faster response times t ...

McKesson (MCK) closed at $821.84 in the latest trading session, marking a -2.22% move from the prior day. This change lagged the S&P 500's daily loss of 2.06%. Elsewhere, the Dow lost 1.76%, while the tech-heavy Nasdaq lost 2.39%. Coming into today, shares of the prescription drug distributor had gained 2.7% in the past month. In that same time, the Medical sector lost 0.88%, while the S&P 500 gained 1.63%. Analysts and investors alike will be keeping a close eye on the performance of McKesson in its upcomi ...

Company Performance - Aurinia Pharmaceuticals (AUPH) has returned approximately 81.2% since the start of the calendar year, significantly outperforming the average gain of 8.2% for Medical stocks [4] - The Zacks Consensus Estimate for AUPH's full-year earnings has increased by 20.3% over the past 90 days, indicating improved analyst sentiment and a stronger earnings outlook [4] - Aurinia Pharmaceuticals is currently ranked 2 (Buy) in the Zacks Rank system, which emphasizes earnings estimates and revisions [3] Industry Comparison - Aurinia Pharmaceuticals is part of the Medical - Drugs industry, which includes 146 stocks and is currently ranked 70 in the Zacks Industry Rank, with an average gain of 9.4% this year [6] - In contrast, Cardinal Health (CAH), another Medical stock, has returned 75.5% since the beginning of the year and is part of the Medical - Dental Supplies industry, which is ranked 102 and has gained 13.3% [5][6] - The Medical group, which includes Aurinia Pharmaceuticals, is currently ranked 6 within the Zacks Sector Rank, which evaluates 16 different sector groups [2]

Core Viewpoint - Cardinal Health's stock performance has been mixed, with a recent increase but a decline over the past month, and upcoming earnings are anticipated to show significant growth in both EPS and revenue [1][2][3]. Company Performance - Cardinal Health's stock rose by 1.93% to $202.95, outperforming the S&P 500's gain of 0.88% [1] - Over the past month, the stock has decreased by 4.23%, underperforming the Medical sector's gain of 1.2% and the S&P 500's gain of 2.48% [1]. Earnings Forecast - The upcoming earnings report is expected to show an EPS of $2.31, reflecting a 19.69% increase from the same quarter last year [2]. - Revenue is forecasted to reach $64.07 billion, indicating a 15.94% rise compared to the previous year [2]. Annual Estimates - For the annual period, earnings are projected at $9.86 per share, with revenue expected to be $258.58 billion, representing increases of 19.66% and 16.18% respectively from last year [3]. Analyst Estimates - Recent modifications to analyst estimates for Cardinal Health are crucial, as positive revisions indicate optimism regarding business and profitability [3]. - The Zacks Consensus EPS estimate has seen a slight downward shift of 0.17% over the past month, and Cardinal Health currently holds a Zacks Rank of 3 (Hold) [5]. Valuation Metrics - Cardinal Health has a Forward P/E ratio of 20.19, which is higher than the industry average of 17.72 [6]. - The company’s PEG ratio stands at 1.45, compared to the Medical - Dental Supplies industry's average PEG ratio of 2.36 [6]. Industry Context - The Medical - Dental Supplies industry, part of the Medical sector, has a Zacks Industry Rank of 151, placing it in the bottom 39% of over 250 industries [7]. - Historically, industries in the top 50% outperform those in the bottom half by a factor of 2 to 1 [7].

Core Insights - The Cooper Companies (COO) is currently more attractive to value investors compared to Merit Medical (MMSI) based on earnings outlook and valuation metrics [3][7] Valuation Metrics - COO has a forward P/E ratio of 17.56, while MMSI has a forward P/E of 22.36 [5] - COO's PEG ratio is 2.26, compared to MMSI's PEG ratio of 2.32, indicating a more favorable earnings growth outlook for COO [5] - COO has a P/B ratio of 1.89, whereas MMSI's P/B ratio is 3.23, suggesting that COO is undervalued relative to its book value [6] Investment Grades - COO has a Zacks Rank of 2 (Buy) and a Value grade of B, while MMSI has a Zacks Rank of 3 (Hold) and a Value grade of C, indicating stronger overall performance for COO [3][6]

Company Performance - Aurinia Pharmaceuticals (AUPH) has returned approximately 72.9% since the beginning of the calendar year, significantly outperforming the average return of 3.9% for Medical companies [4] - The Zacks Consensus Estimate for AUPH's full-year earnings has increased by 20.3% over the past 90 days, indicating improved analyst sentiment and a stronger earnings outlook [3] Industry Comparison - Aurinia Pharmaceuticals is part of the Medical - Drugs industry, which includes 146 individual stocks and currently ranks 84 in the Zacks Industry Rank. The average gain for stocks in this group is 5% year-to-date, highlighting AUPH's superior performance [5] - In contrast, Cardinal Health, which belongs to the Medical - Dental Supplies industry, has returned 67.4% year-to-date, while its industry ranks 99 and has moved up by 9.1% [6]

分组1 - The Cooper Companies reported quarterly earnings of $1.15 per share, exceeding the Zacks Consensus Estimate of $1.11 per share, and showing an increase from $1.04 per share a year ago, resulting in an earnings surprise of +3.60% [1] - The company achieved revenues of $1.07 billion for the quarter ended October 2025, surpassing the Zacks Consensus Estimate by 0.45%, and up from $1.02 billion in the same quarter last year [2] - Over the last four quarters, The Cooper Companies has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] 分组2 - The stock has underperformed the market, losing about 17.4% since the beginning of the year, while the S&P 500 has gained 16.5% [3] - The current consensus EPS estimate for the upcoming quarter is $1.00 on revenues of $1.03 billion, and for the current fiscal year, it is $4.38 on revenues of $4.31 billion [7] - The Medical - Dental Supplies industry, to which The Cooper Companies belongs, is currently ranked in the bottom 38% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Viewpoint - Aurinia Pharmaceuticals (AUPH) is currently outperforming its peers in the Medical sector, with a year-to-date return of 74.6% compared to the sector average of 6.3% [4]. Company Performance - Aurinia Pharmaceuticals is ranked 4 in the Zacks Sector Rank among 949 companies in the Medical group [2]. - The Zacks Rank for AUPH is 2 (Buy), indicating a positive earnings outlook [3]. - The Zacks Consensus Estimate for AUPH's full-year earnings has increased by 20.3% in the past quarter, reflecting stronger analyst sentiment [4]. Industry Context - AUPH is part of the Medical - Drugs industry, which consists of 144 companies and is currently ranked 75 in the Zacks Industry Rank [6]. - The average return for stocks in the Medical - Drugs industry this year is 6.1%, indicating that AUPH is performing significantly better [6]. - Another outperforming stock in the Medical sector is Cardinal Health (CAH), which has a year-to-date return of 77.1% and a Zacks Rank of 2 (Buy) [5].